Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study

Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes

(2015) Jennie H.M. Yang et al.   DIABETES

Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes

(2015) Aixin Yu et al.   DIABETES

Low levels of C-peptide have clinical significance for established Type 1 diabetes

(2015) W. M. Kuhtreiber et al.   DIABETIC MEDICINE

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients

(2015) Michelle Rosenzwajg et al.   JOURNAL OF AUTOIMMUNITY

Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D)

(2015) James Heywood et al.   Trials

Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer

(2014) Guillaume Churlaud et al.   CLINICAL IMMUNOLOGY

Interleukin 2 in the Pathogenesis and Therapy of Type 1 Diabetes

(2014) Michelle Rosenzwajg et al.   Current Diabetes Reports

Most People With Long-Duration Type 1 Diabetes in a Large Population-Based Study Are Insulin Microsecretors

(2014) Richard A. Oram et al.   DIABETES CARE

Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers

(2014) Sawa Ito et al.   MOLECULAR THERAPY

Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial

(2014) F. Waldron-Lynch et al.   BMJ Open

IL-2 therapy in type 1 diabetes: “Trials” and tribulations

(2013) S. Alice Long et al.   CLINICAL IMMUNOLOGY

IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients

(2013) Geok Choo Sim et al.   JOURNAL OF CLINICAL INVESTIGATION

Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease

(2013) K.-i. Matsuoka et al.   Science Translational Medicine

Adaptive dose-finding designs to identify multiple doses that achieve multiple response targets

(2013) Simon Bond et al.   Trials

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial

(2013) Agnès Hartemann et al.   Lancet Diabetes & Endocrinology

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs  -Cell Function

(2012) S. A. Long et al.   DIABETES

Type 1 Diabetes-Associated IL2RA Variation Lowers IL-2 Signaling and Contributes to Diminished CD4+CD25+ Regulatory T Cell Function

(2012) G. Garg et al.   JOURNAL OF IMMUNOLOGY

Metagenomics and Personalized Medicine

(2011) Herbert W. Virgin et al.   CELL

Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

(2011) David Saadoun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

(2011) John Koreth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Etiology of Type 1 Diabetes

(2010) John A. Todd   IMMUNITY

Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects

(2009) S. A. Long et al.   DIABETES

Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource

(2009) Calliope A Dendrou et al.   NATURE GENETICS

Interleukin-2 Therapy in Patients with HIV Infection

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Heterogeneity in Patients With FOXP3 Mutations Presenting With Permanent Neonatal Diabetes

(2008) O. Rubio-Cabezas et al.   DIABETES CARE

CD56brightnatural killer (NK) cells: an important NK cell subset

(2008) Aurélie Poli et al.   IMMUNOLOGY

The IL-2/CD25 Pathway Determines Susceptibility to T1D in Humans and NOD Mice

(2008) Calliope A. Dendrou et al.   JOURNAL OF CLINICAL IMMUNOLOGY